Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Very Strong
Momentum
Price
Strong
Earnings
Weak
Growth
Earnings
Neutral
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
Dimerix LimitedTelephone
61.8.1300.8133
Address
Fitzroy 425 Smith Street Melbourne, Victoria (VIC) 3065
Description
Dimerix Ltd. engages in the investment of the research and development of biopharmaceutical drugs. It focuses on the development of Dimerix DMX-200 drug candidate in both renal and respiratory indications and the development of Dimerix DMX-700 pre-clinical asset in Chronic Obstructive Pulmonary Disease. The company was founded on May 13, 1975 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.13 - 0.67
Trade Value (12mth)
AU$330,877.00
1 week
-5%
1 month
0%
YTD
52%
1 year
123.53%
All time high
44.74
EPS 3 yr Growth
19.30%
EBITDA Margin
%
Operating Cashflow
-$7m
Free Cash Flow Return
-59.90%
ROIC
-141.00%
Interest Coverage
N/A
Quick Ratio
9.50
Shares on Issue (Fully Dilluted)
489m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.08
Date | Announcements |
---|---|
06 November 24 |
Dimerix to Host Technical Webinar on PARASOL FSGS Insights
×
Dimerix to Host Technical Webinar on PARASOL FSGS Insights |
01 November 24 |
NEPTUNE Study Network to Enhance Phase 3 Recruitment in US
×
NEPTUNE Study Network to Enhance Phase 3 Recruitment in US |
31 October 24 |
Quarterly Appendix 4C and Activities Report
×
Quarterly Appendix 4C and Activities Report |
28 October 24 |
Project PARASOL Update & Medical Advisory Board Appointment
×
Project PARASOL Update & Medical Advisory Board Appointment |
25 October 24 |
Change of Director's Interest Notice - CS,HA,NW,SP & MD
×
Change of Director's Interest Notice - CS,HA,NW,SP & MD |
22 October 24 |
Notification regarding unquoted securities - DXB
×
Notification regarding unquoted securities - DXB |
15 October 24 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
01 October 24 |
Chair Address and AGM Presentation
×
Chair Address and AGM Presentation |
01 October 24 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
01 October 24 |
Results of Meeting
×
Results of Meeting |
17 September 24 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
16 September 24 |
ACTION3 Trial Recruitment and Multiregion Trial Site Update
×
ACTION3 Trial Recruitment and Multiregion Trial Site Update |
13 September 24 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
12 September 24 |
First Paediatric Site Activated and Trial Update
×
First Paediatric Site Activated and Trial Update |
11 September 24 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
10 September 24 |
First patient enters into Open Label Extension study
×
First patient enters into Open Label Extension study |
02 September 24 |
Letter to Shareholders, Notice of AGM & Proxy Form
×
Letter to Shareholders, Notice of AGM & Proxy Form |
29 August 24 |
Preliminary Final Report
×
Preliminary Final Report |
29 August 24 |
Annual Report
×
Annual Report |
29 August 24 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
19 August 24 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
15 August 24 |
Notification of Date of 2024 AGM
×
Notification of Date of 2024 AGM |
07 August 24 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
31 July 24 |
Notification of cessation of securities - DXB
×
Notification of cessation of securities - DXB |
31 July 24 |
Change of Director's Interest Notice - HA & SP
×
Change of Director's Interest Notice - HA & SP |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.